Organizational innovativeness and its antecedents: a study of livestock farming technologies

Neste estudo, propõe-se um modelo para explicar a inovatividade dos pecuaristas de gado de corte sob a perspectiva organizacional. Segundo a teoria de difusão de inovações, a inovatividade organizacional é caracterizada como o grau em que uma organização inova relativamente mais cedo do que as demais. Para avaliar a inovatividade, quatro antecedentes foram considerados, sendo: as características percebidas da inovação compostas por vantagem relativa, compatibilidade, imagem, demonstração de resultado, visibilidade, experimentabilidade, voluntariedade e facilidade de uso; a participação dos pecuaristas em redes sociais, caracterizadas como redes de relacionamentos entre pares; as fontes de informação comercial, caracterizadas como informações obtidas por meio dos relacionamentos para reduzir os riscos; a psicografia organizacional, composta por direção, centralidade da decisão, abertura de comunicação e motivação para a conquista. Os quatro construtos possuem uma relação positiva com a inovatividade organizacional. Com amostragem não probabilística por conveniência, foram obtidos 205 questionários válidos. Na análise de componentes múltiplos, observou-se que o perfil dos respondentes se mostrou distinto quanto à inovatividade. Essa distinção motivou a geração de uma taxonomia com base no perfil de adoção de tecnologias com o objetivo de identificar as diferenças no comportamento inovativo, o que resultou em três grupos. Assim, três modelos foram analisados e comparados por meio da modelagem de equações estruturais, utilizando-se o método Partial Least Square (PLS). Os resultados mostraram que o grupo dos menos inovadores pauta suas decisões de adoção de novas tecnologias pelas redes sociais, pela compatibilidade da tecnologia com suas atividades organizacionais e pela imagem que ela tem perante os demais pecuaristas. Os intermediários têm uma psicografia organizacional voltada para a inovatividade, porém a adoção de novas tecnologias parece estar mais relacionada às imposições de mercado do que propriamente à percepção de suas características inovadoras. Os mais inovadores, como formadores de opinião, possuem uma inovatividade organizacional construída a partir de fontes de informação comerciais e avaliam o custo da tecnologia como um investimento positivo para o futuro de seu negócio.En este estudio se propone un modelo para explicar la innovación de los ganaderos productores de carne en la perspectiva de la organización. De acuerdo con la teoría de la difusión de innovaciones, la innovación organizativa se caracteriza por el grado en que una organización es capaz de innovar antes que las demás. Para evaluar la capacidad de innovación, cuatro antecedentes fueron considerados: las características percibidas de la innovación, definidas por ventaja relativa, compatibilidad, imagen, demostración de resultado, visibilidad, experiencia, disposición y facilidad de uso; la participación de los ganaderos en redes sociales, caracterizadas como redes de relaciones entre iguales; las fuentes de información empresarial, caracterizadas por la información obtenida por medio de relaciones para reducir el riesgo; y la psicografía de la organización compuesta por dirección, centralidad de la decisión, apertura de comunicación y motivación de logro. Las cuatro construcciones tienen una relación positiva con la innovación organizativa. Con un muestreo no probabilístico por conveniencia, se obtuvieron 205 cuestionarios válidos. El análisis de componentes múltiples reveló que el perfil de los encuestados es distinto en cuanto a la capacidad de innovación. Esta distinción condujo a la generación de una taxonomía basada en el perfil de adopción de tecnologías con el fin de identificar las diferencias en el comportamiento innovador, lo que dio lugar a tres grupos. Así, se analizaron y compararon tres modelos por medio del modelado de ecuaciones estructurales, con el uso del método PLS (Partial Least Square). Los resultados mostraron que el grupo de los menos innovadores toma sus decisiones de adopción de nuevas tecnologías con base en las redes sociales, en la compatibilidad de la tecnología con sus actividades organizativas y en la imagen que ella tiene ante los otros ganaderos. Los intermediarios tienen una psicografía dirigida hacia la innovación organizativa, sin embargo la adopción de las nuevas tecnologías parece estar más relacionada con las imposiciones del mercado que con la percepción de las características innovadoras de la misma. Los más innovadores, como líderes de opinión, tienen una capacidad de innovación organizativa construida a partir de fuentes comerciales de información y evalúan el costo de la tecnología con una inversión positiva para el futuro de su negocio.This study proposes a model to explain the innovativeness of beef cattle producers from an organizational perspective. According to the innovation dissemination theory, organizational innovativeness is the degree to which an organization innovates relatively sooner than others. To assess innovativeness, four antecedents were considered: the perceived characteristics of innovation, comprised of relative advantage, compatibility, image, result demonstrability, visibility, experimentability, voluntariness and ease of use; the participation of livestock farmers in social networks, characterized as peer relationship networks; sources of commercial information, characterized as information obtained by means of the relationships, in order to reduce risks; and organizational psychographics, consisting of direction, the centrality of decisions, open communication and motivation for achievement. The four constructs have a positive relation with organizational innovativeness. Using a non-random sample for reasons of convenience, 205 valid questionnaires were obtained. The analysis of multiple components showed that the respondents had a distinct profile concerning innovativeness. This distinguishing feature led to the creation of a taxonomy based on the technology adoption profile to identify differences in innovative behavior, which resulted in three groups. Thus, three models were analyzed and compared through structural equation modeling, using the PLS (partial least square) method. The results showed that the group of the less innovative respondents adopted innovations based the social networks, on the compatibility of the technology with their organizational activities and on the new technology's image among the other beef cattle producers. The so-called 'intermediaries' had organizational psychographics geared toward innovativeness; however, the adoption of new technologies seemed to be more related to market dictates than to a perception of the innovative features of these technologies. The most innovative group, i.e., the opinion leaders, demonstrated an organizational innovativeness profile constructed from commercial sources of information and the farmers looked upon the costs of the new technology as a positive investment in the future of the business

THE CHOICE PROCESS OF PRODUCTS IN CONTINUOUS INNOVATION: INNOVATIVENESS, OBJECTIVES OF CONSUMPTION AND PERCEPTION OF INNOVATION

Este estudo, de natureza qualitativa e exploratória, realizado com consumidores de produtos de uso pessoal e em constante inovação, procura explorar as relações que existem entre inovatividade e características percebidas da inovação, durante o processo de decisão dos consumidores. A contribuição do estudo está em conciliar a teoria sobre adoção de inovação aos aspectos comportamentais trazidos pela teoria do processo de escolha, apresentando melhor entendimento do perfil dos adotantes e a forma como tomam suas decisões para a escolha de um produto inovador. Os resultados apontam que o perfil de inovatividade dos entrevistados influencia na forma como os mesmos buscam atingir seus objetivos de consumo durante o processo de escolha. Ao relacionar os objetivos dos consumidores, com diferentes níveis de tendência a inovar, à percepção da inovação, observa-se que as percepções representam uma fonte para que esses consumidores minimizem a possibilidade de uma eventual experiência negativa advinda da decisão, principalmente no que se refere a evitar o arrependimento pela decisão tomada e a justificar a decisão tanto para si quanto para os outros. A compreensão dessas diferenças comportamentais aponta aspectos que devem ser levados em consideração ao se analisar a adoção de produtos dessa natureza.This qualitative and exploratory study, taken with owners of products in constant innovation, analyses the relationship between innovativeness and perceived characteristics of innovation, during the consumers decision-making process. The main contribution of the study is relate the innovation adoption theory with the behavioral aspects of the consumer choice theory, providing a better understanding of the adopters profile and the way they make their decisions for the selection of an innovative product. The results indicate that the degree of innovativeness influences in the way the interviewed achieve their goals during the choice process. The relationship between the consumer goals with different degrees of innovativeness and the innovation perception, allows to observe that these perceptions are a source for those consumers goals to minimise the possibility of a negative experience arising from the decision, especially as regards to avoid regret the decision and the justifiability of the decision for themselves and for others. Understanding these differences suggests behavioral aspects that should be considered relevant to analyse the adoption of such products

Effects of high-intensity interval and moderate-intensity continuous exercise on inflammatory, leptin, IgA, and lipid peroxidation responses in obese males

Purpose: To compare the effects of a single high-intensity interval exercise session (HIIE) with amoderate-intensity continuous exercise session (MICE) on the inflammatory profile, IgA levels, and lipid peroxidation in sedentary obese males. Methods: Ten sedentary obese men (age 28.5 ± 2.7 years; BMI 35.9 ± 4.9 kg/m2; body fat 40.6 ± 2.0%) performed three experimental sessions, on separate days with 1 week wash-out period between interventions, according to a randomized order: (1) HIIE: 10 × 60 s at 90% of the HRmax alternated by 60 s of active recovery; (2) MICE: 20min at 70% of the HRmax; (3) Rest—control. Blood and saliva samples were collected before, immediately after and 60min after the end of each session in order to analyse serum levels of cytokines, IgA, and lipoperoxidation markers. Results: Leptin levels decreased immediately after HIIE (P = 0.033) and was different from the MICE (P = 0.025). IFN-g levels were reduced immediately after (P = 0.032) and 60min after HIIE (P = 0.003) compared to baseline, and it also increased IL-4 levels immediately after exercise (P = 0.007) compared to resting values. MICE promoted an increase in IFN-g levels immediately after exercise (P = 0.025) and 60min after exercise (P = 0.004) in relation to baseline. Both exercise conditions increased IL-6 levels up to 60min after exercise (P < 0.05). The IFN-g/IL-4 ratio decreased immediately after (P = 0.002) and 60min after HIIE (P = 0.005) in relation to pre-exercise. No changes were found for IgA-S and TBARS for any of the conditions. Conclusion: A single HIIE session is able to decrease IFN-g/IL-4 ratio, indicating an anti-inflammatory response, without alterations in the function of the mucosal immune systemand lipoperoxidation. On the other hand, a brief session ofMICE induced changes in the pattern of cytokines associated with increased cellular immune function

ATLANTIC EPIPHYTES: a data set of vascular and non-vascular epiphyte plants and lichens from the Atlantic Forest

Epiphytes are hyper-diverse and one of the frequently undervalued life forms in plant surveys and biodiversity inventories. Epiphytes of the Atlantic Forest, one of the most endangered ecosystems in the world, have high endemism and radiated recently in the Pliocene. We aimed to (1) compile an extensive Atlantic Forest data set on vascular, non-vascular plants (including hemiepiphytes), and lichen epiphyte species occurrence and abundance; (2) describe the epiphyte distribution in the Atlantic Forest, in order to indicate future sampling efforts. Our work presents the first epiphyte data set with information on abundance and occurrence of epiphyte phorophyte species. All data compiled here come from three main sources provided by the authors: published sources (comprising peer-reviewed articles, books, and theses), unpublished data, and herbarium data. We compiled a data set composed of 2,095 species, from 89,270 holo/hemiepiphyte records, in the Atlantic Forest of Brazil, Argentina, Paraguay, and Uruguay, recorded from 1824 to early 2018. Most of the records were from qualitative data (occurrence only, 88%), well distributed throughout the Atlantic Forest. For quantitative records, the most common sampling method was individual trees (71%), followed by plot sampling (19%), and transect sampling (10%). Angiosperms (81%) were the most frequently registered group, and Bromeliaceae and Orchidaceae were the families with the greatest number of records (27,272 and 21,945, respectively). Ferns and Lycophytes presented fewer records than Angiosperms, and Polypodiaceae were the most recorded family, and more concentrated in the Southern and Southeastern regions. Data on non-vascular plants and lichens were scarce, with a few disjunct records concentrated in the Northeastern region of the Atlantic Forest. For all non-vascular plant records, Lejeuneaceae, a family of liverworts, was the most recorded family. We hope that our effort to organize scattered epiphyte data help advance the knowledge of epiphyte ecology, as well as our understanding of macroecological and biogeographical patterns in the Atlantic Forest. No copyright restrictions are associated with the data set. Please cite this Ecology Data Paper if the data are used in publication and teaching events. © 2019 The Authors. Ecology © 2019 The Ecological Society of Americ

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

BACKGROUND: Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI). METHODS: We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate. FINDINGS: The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years (95% uncertainty interval 71·9-78·6) for females and 72·0 years (68·8-75·1) for males. The lowest for females was in the Central African Republic (45·6 years [42·0-49·5]) and for males was in Lesotho (41·5 years [39·0-44·0]). From 1990 to 2016, global HALE increased by an average of 6·24 years (5·97-6·48) for both sexes combined. Global HALE increased by 6·04 years (5·74-6·27) for males and 6·49 years (6·08-6·77) for females, whereas HALE at age 65 years increased by 1·78 years (1·61-1·93) for males and 1·96 years (1·69-2·13) for females. Total global DALYs remained largely unchanged from 1990 to 2016 (-2·3% [-5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. INTERPRETATION: At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for health, including financial and research investments for all countries, regardless of their level of sociodemographic development. The presence of countries that substantially outperform others suggests the need for increased scrutiny for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming countries suggests the need for devotion of extra attention to health systems that need more robust support. FUNDING: Bill & Melinda Gates Foundation

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings